- Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012 - Conditions: Sarcoma; Solid Tumors; Pulmonary Metastases; Lung Metastases; Osteosarcomas; Ewing Sarcoma
Interventions: Drug: Aerosol IL-2; Procedure: Symptom Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Shannon Wilkes Foundation
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: tenofovir disoproxil fumarate; Drug: atazanavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Conditions: Metastatic Cancer; Melanoma
Interventions: Drug: Vemurafenib; Drug: Young TIL; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Cervical Cancer; Oropharyngeal Cancer; Vaginal Cancer; Anal Cancer; Penile Cancer
Interventions: Drug: Fluderabine; Drug: Cycolphosphamide; Biological: Young TIL; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: Efavirenz; Drug: Rilpivirine
Sponsors: Indiana University; Indiana University; Janssen Services, LLC
Not yet recruiting - verified April 2012 - Conditions: Metastatic Cancer; Pancreatic Cancer; Mesothelioma
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Healthy Volunteer
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: efavirenz
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340; Drug: darunavir + cobicistat + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Tuberculosis
Interventions: Drug: PA-824; Drug: Efavirenz (EFV); Drug: Lopinavir/Ritonavir (LPV/r); Drug: Rifampin (RIF)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Plasma Cell Myeloma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Procedure: Apheresis
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Cepheid; Cepheid; AIDS Clinical Trials Group; Centers for Disease Control and Prevention
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Film; Drug: Dapivirine Vaginal Gel
Sponsors: International Partnership for Microbicides, Inc.; International Partnership for Microbicides, Inc.
Not yet recruiting - verified March 2012 - Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel; Drug: Vaginal formulation (VF) of tenofovir 1% gel; Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel; Radiation: Radiolabeling of study drugs and semen
Sponsors: University of Pittsburgh; Ian McGowan; National Institute of Allergy and Infectious Diseases (NIAID); CONRAD
Not yet recruiting - verified April 2012 - Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel; Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel; Drug: Universal HEC Placebo Gel Formulation
Sponsors: University of Pittsburgh; Ian McGowan; National Institute of Allergy and Infectious Diseases (NIAID); CONRAD
Not yet recruiting - verified April 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Hydroxychloroquine; Drug: IL-2
Sponsors: University of Pittsburgh; University of Pittsburgh; Prometheus Laboratories
Recruiting - verified March 2012 - Condition: HIV
Intervention: Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Sponsors: Fenway Community Health; Kenneth H. Mayer, MD; Bristol-Myers Squibb; Gilead Sciences; Abbott
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Conditions: HIV; Patient Compliance
Interventions: Behavioral: Positive Choices; Behavioral: Personalized Cognitive Counseling
Sponsors: Columbia University; Columbia University; National Institute of Mental Health (NIMH)
Not yet recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Drug: Lamivudine; Drug: Tenofovir disoproxil fumarate
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified February 2012 - Condition: HIV Infection
Interventions: Drug: Maraviroc; Drug: Emtricitabine; Drug: Tenofovir disoproxil fumarate; Other: Maraviroc placebo; Other: Emtricitabine placebo; Other: Tenofovir disoproxil fumarate placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention Trials Network
Not yet recruiting - verified May 2012 - Condition: Endothelial Dysfunction
Intervention: Drug: Telmisartan
Sponsors: University of California, Los Angeles; University of California, Los Angeles; The Campbell Foundation
Not yet recruiting - verified April 2012 - Conditions: Mestatic Melanoma; Skin Cancer
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Drug: Aldesleukin; Drug: MART-1 Reactive CD8+ PBL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Cervical Cancer
Interventions: Drug: Nelfinavir; Drug: Cisplatin; Radiation: Pelvic External Beam Radiation Therapy; Radiation: Brachytherapy; Procedure: Pharmacokinetic Sampling; Procedure: Cervical Biopsy; Procedure: Pelvic Examination; Procedure: Pap Smear; Procedure: Audiogram; Procedure: Proctoscopy; Procedure: Cytoscopy; Procedure: Renal Ultrasound; Procedure: CT Scan; Procedure: Whole Body PET/CT Scan
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting - verified December 2011 - Conditions: HIV; PCP; Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily; Drug: Atovaquone 1500 mg twice daily
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified October 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Adult Liposarcoma; Adult Synovial Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: recombinant interferon gamma; Biological: aldesleukin; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: biopsy; Biological: NY-ESO-1-specific T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium; Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug: Pravastatin sodium
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: Hodgkin Disease; Hodgkin Lymphoma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Drug: Yttrium-Daclizumab (CHX-A Daclizumab); Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Ca(2+)-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Sarcoma, Kaposi
Intervention: Drug: Pomalidomide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Human Immunodeficiency Virus
Intervention: Drug: Atripla (EFV/TDF/FTC); boosted darunavir & tenofovir/FTC; boosted atazanavir & tenofovir/FTC; raltegravir & tenofovir/FTC
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Malignant Glioma; Glioblastoma; Brain Cancer
Interventions: Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD; Drug: darunavir 800mg OAD; Drug: ritonavir 100mg OAD
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Castleman Disease; Castleman's Disease; Giant Lymph Node Hyperplasia
Interventions: Drug: Zidovudine; Drug: Tocilizumab; Drug: Valganciclovir
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: ribavirin
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: Cobicistat; Drug: Darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2011 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Herpes Simplex Type II
Interventions: Drug: Tenofovir; Drug: placebo gel; Drug: tenofovir disoproxil fumarate (TDF); Drug: placebo tablets
Sponsors: University of Washington; University of Washington; CONRAD; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV
Interventions: Drug: Twice-daily Darunavir/ritonavir; Drug: Once-daily Darunavir/ritonavir
Sponsors: Ruth M. Rothstein CORE Center; Ruth M. Rothstein CORE Center; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Not yet recruiting - verified January 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Atazanavir
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institutes of Health (NIH)
Not yet recruiting - verified August 2011 - Conditions: Hepatitis; HIV/AIDS
Interventions: Drug: Boceprevir; Drug: Peg-Interferon-alfa 2B; Drug: Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Conditions: KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir; Drug: Rituximab/Liposoma Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rifaximin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Myeloma
Interventions: Drug: G-CSF; Drug: Plerixafor; Procedure: Apheresis; Drug: Melphalan; Procedure: Stem cell re-infusion; Drug: Basiliximab; Device: CliniMACS CD25 microbeads and cell sorter
Sponsors: University of Chicago; University of Chicago
Recruiting - verified January 2012 - Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel; Drug: Depo-medroxyprogesterone acetate (DMPA); Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
Sponsors: CONRAD; CONRAD
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Drug: Ipilimumab; Drug: Temozolomide; Drug: Cisplatin; Drug: Interferon Alfa-2b; Drug: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified February 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: etoposide; Procedure: leukapheresis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: Atripla; Drug: Calcium Carbonate; Drug: Vitamin D3; Drug: Placebo for calcium carbonate; Drug: Placebo for vitamin D3
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV-1 Infection
Interventions: Drug: Darunavir; Drug: Ritonavir; Drug: Tenofovir disoproxil fumarate; Drug: Emtricitabine; Drug: Placebo for Tenofovir disoproxil fumarate; Drug: Placebo for Maraviroc
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified September 2011 - Conditions: Hepatitis C; HIV
Intervention: Drug: boceprevir; etravirine
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified August 2011 - Condition: Neuroblastoma
Interventions: Drug: Zoledronic Acid; Biological: Aldesleukin
Sponsors: University of Alabama at Birmingham; Joseph Pressey, MD
Recruiting - verified December 2011 - Condition: HIV Infected
Intervention: Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Leukemia; Chronic Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Procedure: NK cell infusion:; Drug: Interleukin-2; Drug: Anti-Thymocyte Globulin; Procedure: Allogeneic related Stem Cell Transplant; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: HIV Infection; Hepatitis C
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors: Duke University; Duke University; Celgene Corporation; Genzyme
Recruiting - verified January 2012 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Aldesleukin; Biological: Tumor Infiltrating Lymphocytes
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: HIV Prevention
Intervention: Drug: Tenofovir 1% vaginal gel
Sponsors: CONRAD; CONRAD
Recruiting - verified March 2012 - Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified February 2012 - Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Ring; Drug: Maraviroc Vaginal Ring; Other: Placebo Vaginal Ring; Drug: Dapivirine-Maraviroc Vaginal Ring
Sponsors: International Partnership for Microbicides, Inc.; International Partnership for Microbicides, Inc.
Recruiting - verified November 2011 - Condition: Diabetic Ulcer
Intervention: Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors: New York University School of Medicine; New York University School of Medicine; National Institutes of Health (NIH); Genzyme
Not yet recruiting - verified May 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg; Drug: Cenicriviroc 200 mg + Truvada; Drug: Sustiva + Truvada
Sponsors: Tobira Therapeutics, Inc.; Tobira Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: Acute Myeloid Leukemia
Interventions: Drug: plerixafor; Drug: decitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Genzyme
Recruiting - verified June 2011 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Drug: cyclophosphamide; Biological: aldesleukin; Biological: autologous tumor cell vaccine; Other: laboratory biomarker analysis; Other: immunologic technique; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Biological: therapeutic autologous lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: HIV Disease
Interventions: Drug: HAART regimen; Drug: 3TC or FTC monotherapy
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Conditions: Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions: Drug: Plerixafor; Drug: Filgrastim
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Condition: HIV
Interventions: Drug: Atazanavir Sulphate; Drug: Ritonavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus (HIV) Infection
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV, Combination Therapy
Interventions: Drug: Atazanavir; Drug: Ritonavir (heat-stable); Drug: Raltegravir; Drug: Tenofovir/Emtricitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor; Drug: Plerixafor; Drug: Bevacizumab; Drug: Plerixafor; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genzyme
Recruiting - verified February 2012 - Conditions: Alcohol Consumption; Unsafe Sex
Interventions: Behavioral: Brief Motivational Intervention (BMI); Behavioral: Brief Advice
Sponsors: Brown University; Brown University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Memorial Hospital of Rhode Island; Kent Hospital
Recruiting - verified November 2011 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young Tumor Infiltrating Lymphocytes; Procedure: 1200 Gy Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Fanconi Anemia
Interventions: Biological: filgrastim; Drug: plerixafor; Procedure: leukapheresis; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL
Intervention: Drug: Plerixafor Dose Escalation
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Microbicide Delivery System Acceptability
Intervention:
Sponsors: The Miriam Hospital; The Miriam Hospital; ImQuest Pharmaceuticals, Inc.; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Transplantation Infection
Interventions: Drug: Cidofovir; Other: No Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: HIV
Interventions: Drug: Raltegravir; Drug: Efavirenz
Sponsors: University of California, San Diego; University of California, San Diego; Merck
Recruiting - verified January 2012 - Conditions: Hazardous Drinking; HIV
Intervention: Behavioral: Brief alcohol intervention
Sponsors: Brown University; Brown University
Recruiting - verified October 2011 - Conditions: HIV Infection; Hepatitis C
Interventions: Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: HIV Infection
Intervention: Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Abbott
Recruiting - verified May 2012 - Condition: Failure of Bone Marrow Graft
Intervention: Drug: Plerixafor
Sponsors: Duke University; Duke University; Genzyme
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV Infection
Intervention: Drug: Interferon Alpha 2b
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: Melanoma (Skin)
Interventions: Biological: aflibercept; Biological: aldesleukin
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: HIV-1
Interventions: Drug: lersivirine; Drug: lersivirine; Drug: efavirenz; Drug: lersivirine; Drug: lersivirine; Drug: etravirine
Sponsors: Pfizer; Pfizer; ViiV Healthcare
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus
Intervention: Drug: emtricitabine/tenofovir disoproxil fumarate
Sponsors: Henry Ford Health System; Henry Ford Health System
Recruiting - verified June 2011 - Conditions: Alcohol Abuse; Alcohol Dependence
Interventions: Drug: ondansetron; Drug: placebo ondansetron; Drug: Ondansetron
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012 - Conditions: Metastatic Cancer; Metastatic Melanoma; Renal Cancer
Interventions: Genetic: Anti-VEGFR2 CAR CD8 plus PBL; Drug: Cyclophosphamide; Drug: Aldesleukin; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Merck; Gilead Sciences
Recruiting - verified February 2012 - Conditions: Bacterial Vaginosis; Trichomoniasis; Candidiasis
Interventions: Drug: Placebo; Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Healthy Adult Females
Intervention: Other: Pharmacokinetic Sampling
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Recruiting - verified March 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV); Drug: tenofovir/emtricitabine (TDF/FTC); Drug: Atazanavir (ATV); Drug: Ritonavir; Procedure: Phlebotomy
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Society of Infectious Diseases Pharmacists; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Metastatic Colorectal Cancer; Metastatic Gastric Cancer; Metastatic Pancreatic Cancer; Metastatic Hepatocellular Carcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: CD8+ young TIL; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Biological: rituximab; Drug: EPOCH regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim) plus Plerixafor Injection; Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors: Genzyme; Genzyme
Recruiting - verified April 2012 - Condition: Acute Myelogenous Leukemia
Interventions: Drug: Plerixafor; Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified April 2012 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma
Intervention: Drug: Sargramostim and plerixafor
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified November 2011 - Conditions: Hepatitis C; HIV
Intervention: Drug: Pegylated interferon with ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); Fundacion de Investigacion de Diego
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Drug: Tenofovir 1% gel; Other: Placebo gel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Risk Reduction Behavior; Health Behavior; Sexual Behavior; Adolescent Behavior; Cannabis
Interventions: Behavioral: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY); Behavioral: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH); Behavioral: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION
Sponsors: University of New Mexico; University of New Mexico; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified August 2011 - Condition: Normal Volunteer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Nelfinavir
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: filgrastim; Drug: plerixafor; Biological: rituximab; Drug: ifosfamide; Drug: carboplatin; Drug: etoposide; Procedure: leukapheresis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Hazardous Alcohol Use; Binge Drinking; High Risk Sexual Behaviors; HIV Risk Reduction; HIV Infection
Interventions: Behavioral: Computerized brief alcohol intervention with IVR booster calls; Behavioral: Computer delivered brief alcohol intervention; Behavioral: Attention Control
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified June 2011 - Conditions: Myeloma; Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Emory University; Emory University; Genzyme
Recruiting - verified March 2012 - Conditions: Birth Defects; Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Ependymoblastoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Grade III Meningioma; Meningeal Hemangiopericytoma; Mixed Glioma; Pineal Gland Astrocytoma; Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: cyclophosphamide; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Intervention: Drug: Plerixafor
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme
Recruiting - verified November 2011 - Conditions: Carcinoma, Adenoid Cystic; Head and Neck Neoplasms
Intervention: Drug: Nelfinavir
Sponsors: University of Iowa; University of Iowa; Holden Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndromes
Interventions: Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: Adenocarcinoma of the Pancreas; Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery; Other: pharmacological study; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Genetic: protein expression analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Hepatitis C
Interventions: Other: Ribavrin; Drug: Abacavir plus Ribavirin
Sponsors: Johns Hopkins University; Johns Hopkins University; GlaxoSmithKline; University of Nebraska
Recruiting - verified January 2010 - Condition: Lymphoma
Interventions: Drug: lenalidomide; Drug: temsirolimus; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified November 2010 - Conditions: Multiple Myeloma; Non-Hodgkins Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Shi, Patricia, M.D.; Shi, Patricia, M.D.; Genzyme
Recruiting - verified September 2011 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011 - Condition: HIV Infections
Interventions: Drug: Emtricitabine (FTC); Drug: Tenofovir disoproxil fumarate (TDF); Drug: Efavirenz (EFV)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: Aldesleukin
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Conditions: HIV; HIV Infections
Intervention: Drug: Valacyclovir
Sponsors: University of Washington; University of Washington
Recruiting - verified November 2011 - Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Stem Cell Transplant Patients
Intervention: Drug: G-CSF +/- AMD3100
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: ritonavir; Procedure: therapeutic conventional surgery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012 - Condition: High Risk Non-Hodgkin's Lymphoma
Interventions: Biological: Rituximab; Biological: Interleukin-2
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012 - Condition: Hepatitis B
Interventions: Drug: Simvastatin; Drug: Tenofovir; Drug: Entecavir
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Recruiting - verified June 2011 - Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Lymphoma; B-cell Lymphoma
Interventions: Procedure: Leukapheresis; Procedure: Stem Cell Transplant; Procedure: CD19-specific T Cell Infusion; Drug: IL-2; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: WHIMS; Neutrophil Disorder; Myelokathexis; Hypogammaglobulinemia
Intervention: Drug: Mozobil (TM)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: tenofovir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention: Drug: Etravirine (Intelence)
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Janssen Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Cystitis; Bladder Diseases
Intervention: Drug: Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Gilead Sciences
Not yet recruiting - verified March 2012 - Conditions: Hodgkin Lymphoma; Non Hodgkin Lymphoma; Kaposi's Sarcoma; Gastric Cancer; Nasopharyngeal Cancer
Interventions: Other: FIAU-PET-CT scans; Other: FIAU-PET-CT scan
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Acute Myelogenous Leukemia; Leukemia
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Genzyme; Onyx Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Large Cell Lymphoma
Interventions: Genetic: Anti-CD19-CAR Transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Acute HIV Infection; HIV Infections
Intervention: Drug: Atripla
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Bristol-Myers Squibb; Gilead Sciences
Recruiting - verified December 2011 - Conditions: Renal Cancer; Kidney Cancer
Interventions: Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100); Drug: bortezomib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Genzyme
Recruiting - verified May 2012 - Condition: Leukemia, Myeloid, Acute
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Mitoxantrone; Drug: Etoposide; Drug: Cytarabine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: HIV Infections; Drug Abuse
Interventions: Drug: Disulfiram; Drug: Disulfiram + Efavirenz; Drug: Disulfiram + Atazanavir; Drug: Disulfiram + Ritonavir
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Drug: cyclophosphamide; Procedure: biopsy; Biological: aldesleukin; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Other: immunoenzyme technique; Biological: therapeutic allogeneic cytotoxic T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Alcohol; Drug: Alcohol placebo
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Conditions: Cryptococcal Meningitis; HIV Infections
Interventions: Drug: Fluconazole; Drug: Amphotericin B
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: ritonavir; Drug: TMC125 (etravirine); Drug: TMC278 (rilpivirine); Drug: TMC114 (darunavir)
Sponsors: Tibotec, Inc; Tibotec, Inc; Janssen Services, LLC
Recruiting - verified May 2012 - Conditions: Acute HIV Infection; HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Janssen Pharmaceuticals
Recruiting - verified December 2011 - Conditions: HIV Infection; Cardiovascular Disease; Inflammation; HIV Infections
Interventions: Drug: Maraviroc; Drug: placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI); Pfizer
Recruiting - verified November 2011 - Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
Interventions: Drug: Raltegravir; Drug: Atazanavir; Other: Standard treatment regimen
Sponsors: Yale University; Yale University; Bristol-Myers Squibb; Merck
Recruiting - verified February 2012 - Condition: HIV Infections
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: allogeneic large multivalent immunogen breast cancer vaccine; Biological: aldesleukin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Conditions: HSV-2; HIV; HIV Infections
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; GlaxoSmithKline
Recruiting - verified August 2011 - Conditions: HIV Infections; HIV-1
Intervention: Drug: TMC278
Sponsors: Tibotec Pharmaceuticals, Ireland; Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2012 - Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease
Interventions: Drug: AMD3100; Drug: G-CSF; Procedure: Apheresis
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Metastatic Melanoma; Metastatic Renal Cell Cancer; Metastatic Cancer
Interventions: Biological: therapeutic autologous lymphocytes; Biological: aldesleukin; Drug: cyclophosphaide; Drug: fludarabine phosphate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: HIV Infections
Intervention: Drug: ARV regimen chosen by treating physician
Sponsors: University of North Carolina, Chapel Hill; Kristine Patterson, MD; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Biological: EGFRBi-armed autologous activated T cells; Biological: aldesleukin; Biological: sargramostim
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Condition: HIV Infections
Intervention: Drug: Cell Transfer
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012 - Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Tenofovir/ & Emtricitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
Recruiting - verified May 2012 - Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Conditions: Metastatic Melanoma; Renal Cell Cancer
Intervention: Biological: aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified March 2012 - Conditions: AIDS-Related Primary Central Nervous System Lymphoma; HIV
Interventions: Drug: Methotrexate; Biological: rituximab; Procedure: antiviral therapy; Drug: leucovorin calcium
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified January 2012 - Condition: HIV Infections
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; HIV Infection; HIV-associated Hodgkin Lymphoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Healthy
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Conditions: Healthy; Blood Component Removal
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Current ARV medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Severe Combined Immunodeficiency Syndrome
Intervention: Drug: CD34+ cells transduced with ADA retrovir
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012
 |
Anti HIV Agents Clinical Trials |
